Drug intelligence / Profile preview

MEL-P15

Development stage: Preclinical
Lead developer: Cerapedics
Modality: Peptides

Overview

MEL-P15 is a peptide derived from **melittin**, which is the main toxic component in the venom of the European honeybee (Apis mellifera). MEL-P15 has been specifically studied for its **anti-hepatocellular carcinoma activity**, demonstrating cytotoxic effects against liver cancer cells. The mechanism of action is related to its peptide structure, which influences cell membrane permeability and induces cell death in cancer cells. Its activity is distinct from native melittin in terms of selectivity and toxicity profile[3].

Beyond the preview

Go deeper on MEL-P15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEL-P15.

Explore the full profile